Limb-Girdle Muscular Dystrophy (LGMD) is a genetic disorder affecting 0.8–6.9 individuals per 100,000 worldwide and characterized by progressive muscle weakness, loss of mobility, and, in severe cases, cardiomyopathy and respiratory failure. LGMD comprises more than 30 genetically distinct subtypes, each caused by mutation(s) affecting protein(s) essential for muscle maintenance and repair. Subtype LGMD2I (LGMDR9) is an early onset subtype caused by mutations in the fukutin-related protein (FKRP) gene, leading to impaired glycosylation of α-dystroglycan, a critical protein required for maintaining muscle fiber integrity. The resulting loss of muscle stability drives progressive muscle degeneration, highlighting the need for therapies that can restore FKRP function and halt disease progression.

This technology is a novel FKRP gene therapy transgene designed to treat Limb-Girdle Muscular Dystrophy type 2I (LGMD2I) and related FKRP-associated disorders. By enhancing the activity of the FKRP protein, the engineered transgene more effectively restores α-dystroglycan glycosylation, a critical process required for maintaining muscle integrity. In preclinical studies, the transgene demonstrated improved efficacy compared to wild-type FKRP while requiring lower doses, which may reduce the risks of immunogenicity and toxicity associated with gene therapy. Researchers developing gene therapies for muscular dystrophies may benefit from this approach because its enhanced potency offers the potential for improved therapeutic outcomes while addressing key safety and dosing challenges that have limited existing gene replacement strategies.

 

Researchers and commercial partners interested in advancing this technology should contact the university's technology transfer office to discuss licensing opportunities, as the university is seeking to partner with qualified entities for continued development, regulatory clearance, and eventual market introduction of the technology.

Technology Overview

Current Challenges

Current FKRP gene therapies often require high vector doses, which can increase immunogenicity and cause expression-related toxicity, creating risks of serious adverse events. These safety concerns may limit therapeutic efficacy and broader clinical adoption. This novel FKRP transgene addresses these challenges by delivering enhanced biological activity at lower doses, potentially improving both the efficacy and safety of gene replacement therapy for LGMD2I and other FKRP-associated disorders.

Our Innovation

This novel FKRP transgene sequence has been engineered to address the risk of severe complications associated with high dose transgene and hence safeguard the success of FKRP gene therapy. The design of the novel FKRP transgene was derived from its recently identified working mechanism. Compared to the wild-type FKRP, this novel transgene design exhibited significantly improved efficacy in restoring glycosylation of α-DG in a LGMD mouse model.   

With the reduced requirement of transgene dose and hence better safety profile, the novel FKRP transgene could be used alone or in combination with small molecule (e.g. Ribitol) and or additional transgene(s). FKRP related conditions beyond LGMD are suitable for gene therapy with this novel FKRP transgene. 

Benefits of this Technology

  • Higher efficacy: higher activity with the same amount of FKRP protein expressed. 
  • Better safety profile: decreased immunogenicity with lowered dose requirement; Reduced toxicity with lower copy of genes required per cell. 

Stage of Development

The novel FKRP transgene has been designed and evaluated in preclinical studies, demonstrating enhanced restoration of α-dystroglycan glycosylation compared with the wild-type FKRP transgene. Efficacy has been validated in an LGMD mouse model following systemic intravenous administration, providing proof-of-concept for its potential as a gene replacement therapy. These findings support continued development and optimization of the transgene for translation toward clinical applications in LGMD2I and other FKRP-associated disorders.